Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Gen Z workers are increasingly worried AI could replace their jobs. However, experts say companies are using AI more to assist workers than replace them.
Matt Schultz of CleanSpark discusses Bitcoin mining and AI infrastructure converge, energy demand dynamics, and the company’s position in the evolving market.
Bhavin Shah of ServiceNow discusses how the new Autonomous Workforce AI automates tasks, integrates with Teams and Slack, and boosts workplace efficiency.
Angi is partnering with OpenAI to bring its home services marketplace directly into ChatGPT, allowing users to go from questions to booking local pros.
Tech stocks are rallying on strong earnings and massive AI investment. Investors are watching Nvidia & hyperscaler spending for clues on how long it will last.
